A biochemical and immunocytochemical study on the targeting of alglucerase in murine liver.
A current hypothesis is that functional glucocerebrosidase needs to be delivered to the lysosomes of tissue macrophages to guarantee successful enzyme therapy for Gaucher's disease. In this study, biochemical and immunohistochemical techniques were applied to identify in mice the localization of intravenously administered alglucerase (human modified placental glucocerebrosidase). Only in liver and spleen was a significant increase of glucocerebrosidase activity observed, with a maximum level at 15 minutes after enzyme infusion. The uptake of enzyme by liver was sufficiently high to allow more detailed studies on the (sub)cellular distribution of human alglucerase. The enzyme in liver is localized both in the endosomal-lysosomal system of the Kupffer cells and the endothelial cells lining the lumen of the sinusoids. Uptake by both of these types of cell is prevented by mannan. The results suggest that the cellular mechanisms responsible for improvement of Gaucher patients receiving alglucerase treatment is probably more complicated than previously recognized.
Department of Clinical Genetics, Erasmus University, Rotterdam, The Netherlands.
R
R
Willemsen
J J
JJ
Tibbe
M A
MA
Kroos
B M
BM
Martin
A J
AJ
Reuser
E I
EI
Ginns
D000818:Animals; D016616:Cryoultramicrotomy; D005260:Female; D005962:Glucosylceramidase / Q000493:pharmacokinetics*; D006801:Humans; D007150:Immunohistochemistry; D007275:Injections, Intravenous; D008099:Liver / Q000166:cytology / Q000201:enzymology*; D051379:Mice; D008815:Mice, Inbred Strains; D013347:Subcellular Fractions / Q000201:enzymology; D014018:Tissue Distribution
C070292:alglucerase; D005962:Glucosylceramidase